PHARMACEUTICAL COMPOSITION TO TREAT LOCALLY ADVANCED PANCREAS CANCER (CPLA) NOT REMOVABLE.

摘要

Use of an adenoviral vector, which comprises a nucleic acid sequence encoding a human FNT-α and that is operably linked to a radiation inducible promoter, in the manufacture of a pharmaceutical composition for treating locally advanced pancreatic cancer (CPLA) not removable in a human being, in which (a) a dose of the pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) from about 4 x 107 to about 4 x 1012 particle units (up) will be administered. of said adenoviral vector locally in a human tumor approximately once a week in a therapeutic period comprising approximately 3-8 weeks; (b) a dose of ionizing radiation will be administered to the human being during the therapeutic period; and (c) a dose of one or more chemotherapeutic agents will be administered to the human during the therapeutic period.